Sign in
Taking people in South KoreaNo phase

Tests a drug-coated balloon versus standard stents for coronary artery disease

Compares a drug-coated balloon with standard stent treatment in adults with coronary artery disease.

Key facts

Who runs it
Boston Scientific Corporation
Where
Seoul, South KoreaSee the 2 sitesAlso in 8 other countries, 69 sites
Trial code
Registry title
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Status
Recruiting
People taking part
1,616 people, planned
Started
21 Aug 2025
Expected to end
Mar 2032
Type of study
Interventional, 8 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Drug Eluting Balloon
  • Drug eluting stent
  • Plain old balloon angioplasty
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with new (de novo) narrowing in a native heart artery who can have a coronary stent or balloon procedure (PCI). It compares a drug-coated balloon with standard PCI.

Age
18 years or older
Sex
All sexes
Disease stage
A new (de novo) narrowing in a native coronary artery. Narrowing of more than 50% and less than 100% if there are symptoms, more than 70% and less than 100% if there are none. The narrowing must be successfully pre-dilated.
Earlier treatment
No PCI or other coronary procedure within the last 3 days. No planned PCI or bypass surgery after the trial procedure. No previous heart transplant.

Main reasons for not taking part

  • Stent re-narrowing (in-stent restenosis), a fully blocked artery or a clot in the artery
  • Severe calcium in the artery, or a lesion that needs atherectomy or lithotripsy
  • Heart attack (STEMI or QWMI) less than 72 hours before the procedure, or shock
  • Kidney failure needing dialysis, or creatinine of 2.0 mg/dl (177 µmol/L) or higher
  • Pregnant or nursing women

The registry criteria, word for word

Show all 38 criteriaShow less

Other criteria

  • Clinical Inclusion Criteria:
  • Subject must be at least 18 years of age
  • Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
  • Subject is eligible for percutaneous coronary intervention (PCI)
  • Subject is willing to comply with all protocol-required follow-up evaluation
  • Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure; Angiographic Inclusion Criteria:
  • Target lesion is a de novo lesion located in a native coronary artery
  • Target lesion must have visually estimated stenosis > 50% and < 100% in symptomatic subjects (>70% and <100% in asymptomatic subjects) prior to lesion pre-dilation
  • Target lesion must be successfully pre-dilated
  • If a non-target lesion is treated, it must be treated first and must be deemed a success; Clinical Exclusion Criteria:
  • Subject has other serious medical illness (e.g. cancer, congestive heart failure) that may reduce life expectancy to less than 12 months
  • Subject has current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc.) as assessed by Investigator
  • Subject has planned procedure that may cause non-compliance with the protocol or confound data interpretation
  • Subject is participating in another investigational drug or device clinical study that has not reached its primary endpoint
  • Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure
  • Subject is a woman who is pregnant or nursing. A pregnancy test must be performed within 7 days prior to the index procedure, except for women who definitely do not have child-bearing potential
  • Subject has left ventricular ejection fraction known to be < 30% within the last 12 months
  • Subject had PCI or other coronary interventions within the last 3 days
  • Subject has planned PCI or CABG after the index procedure
  • Subject had STEMI or QWMI <72h prior to the index procedure
  • Subject presents with ACS and rising biomarkers, or ongoing chest pain or is hemodynamically unstable
  • Subject has cardiogenic shock (SBP < 80 mmHg requiring inotropes, IABP or fluid support)
  • Subject has history (within 6 months prior to the index procedure) of New York Heart Association (NYHA) class III or IV heart failure
  • Subject is considered not able to tolerate at least 30 seconds of coronary occlusion of the target lesion
  • Subject has known allergy to paclitaxel or other components of the used medical devices
  • Subject has known hypersensitivity or contraindication to contrast dye that in the opinion of the investigator cannot be adequately pre-medicated
  • Subject has intolerance to antiplatelet drugs, anticoagulants required for procedure
  • Subject has platelet count < 100k/mm3 (risk of bleeding) or > 700k/mm3
  • Subject with renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent)
  • Subject has previous or planned (within 30 days) TAVR
  • Previous cardiac transplant; Angiographic Exclusion Criteria:
  • In-stent restenosis
  • Target lesion is located within a saphenous vein or arterial graft
  • Target lesion is a total occlusion or has evidence of thrombus present in the target vessel
  • Target lesion is severely calcified by angiography or has > 270° calcium arc on intravascular imaging or requires atherectomy or requires intravascular lithotripsy
  • Subject has unprotected left main coronary artery disease (>50% diameter stenosis) or three-vessel coronary disease requiring revascularization of all 3 vessels
  • Subject with planned treatment of lesion involving aortic ostial location <3 mm from aorta
  • Target Lesion is in a previously jailed side branch

Where in South Korea

Also in 8 other countries, 69 sites

  • Asan Medical CenterSeoul, South KoreaContact: Jung-Min Ahn, MDTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Joo Myung Lee, MDTaking people

About the trial

What the trial wants to find out

AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions.

Read full original descriptionShow less

Subjects must have a de novo target lesion located in a native coronary artery.

The 8 groups in the trial

  • Small Vessel - TestTreatment being tested

    Small vessel subjects treated with AGENT DCB

    Treatment: Drug Eluting Balloon

  • Small Vessel - ControlExisting treatment, for comparison

    Small vessel subjects treated with drug eluting stent

    Treatment: Drug eluting stent

  • Bifurcation - TestTreatment being tested

    Bifurcation subjects with side branches treated with AGENT DCB

    Treatment: Drug Eluting Balloon

  • Bifurcation - ControlExisting treatment, for comparison

    Bifurcation subjects with side branches treated with drug eluting stent or plain old balloon angioplasty

    Treatment: Drug eluting stent and Plain old balloon angioplasty

  • Long Lesion - TestTreatment being tested

    Long lesion subjects treated with AGENT DCB

    Treatment: Drug Eluting Balloon

  • Long Lesion - ControlExisting treatment, for comparison

    Long lesion subjects treated with drug eluting stent

    Treatment: Drug eluting stent

  • Overall - TestTreatment being tested

    All subjects treated with AGENT DCB

    Treatment: Drug Eluting Balloon

  • Overall - ControlExisting treatment, for comparison

    All subjects treated with standard of care drug eluting stent and/or POBA

    Treatment: Drug eluting stent and Plain old balloon angioplasty

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
AGENT DCB STANCE: AGENT Drug-Coated Balloon for STent AvoidANCE in PCI for De Novo Coronary Artery Disease
Plain-language title
Tests a drug-coated balloon versus standard stents for coronary artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 October 2026